321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
The Readout Loud
00:00
Intro
This chapter explores the promising potential of amylin hormones as an obesity treatment with fewer side effects than current options. Additionally, it highlights a cancer drug's impressive performance over Merck's Keytruda and features a sponsorship from Johnson & Johnson focused on oncology advancements.
Transcript
Play full episode
